Exametazime

Technetium (<sup>99m</sup>Tc) exametazime

Technetium (99mTc) exametazime

Chemical compound


Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke[1] and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections[2] and inflammatory bowel disease.[3] Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are:[4]

  • (NE)-N-[(3R)-3-[[3-[[(2R,3E)-3-hydroxyiminobutan-2-yl]amino]-2,2-dimethylpropyl]amino]butan-2-ylidene]hydroxylamine
  • or 3,3'-((2,2,-dimethyl-1,3-propanediyl)diimino)bis-2-butanone dioxime.
Quick Facts Clinical data, Trade names ...

Chemistry

One of the two enantiomers of exametazime

The drug consists of exametazime as a chelating agent for the radioisotope technetium-99m. Both enantiomeric forms of exametazime are used—the drug is racemic.[5] The third stereoisomer of this structure, the meso form, is not included.


References

  1. Moretti JL, Defer G, Cinotti L, Cesaro P, Degos JD, Vigneron N, et al. (1990). ""Luxury perfusion" with 99mTc-HMPAO and 123I-IMP SPECT imaging during the subacute phase of stroke". European Journal of Nuclear Medicine. 16 (1): 17–22. doi:10.1007/BF01566007. PMID 2307169. S2CID 11934803.
  2. Ui K, Yamaguchi T (December 1991). "[Therapy and diagnosis of emergency shock patients]". Nihon Naika Gakkai Zasshi. The Journal of the Japanese Society of Internal Medicine. 80 (12): 1892–6. doi:10.2169/naika.80.1892. PMID 1804909.

Share this article:

This article uses material from the Wikipedia article Exametazime, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.